You are here

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
805 Oncolytic adenovirus encoding human interleukin-7 in combination with ICIs as a treatment strategy against renal cell carcinoma (RCC)

Authors

  • Victor Arias Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Tatiana Kudling Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • James Clubb Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland TILT Biotherapeutics, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Lyna Haybout Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland TILT Biotherapeutics, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Elise Jirovec Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Santeri A Pakola Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Saru Basnet University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Dafne CA Quixabeira Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland TILT Biotherapeutics, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Otto Hemminki Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland Department of Urology, Helsinki University Hospital, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Susanna AM Grönberg-Vähä-Koskela Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Joao Manuel Santos Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland TILT Biotherapeutics, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Victor Cervera-Carrascon Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland TILT Biotherapeutics, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Akseli Hemminki Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland TILT Biotherapeutics, Helsinki, Finland Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland PubMed articlesGoogle scholar articles

Citation

Arias V, Kudling T, Clubb J, et al
805 Oncolytic adenovirus encoding human interleukin-7 in combination with ICIs as a treatment strategy against renal cell carcinoma (RCC)
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0805

Publication history

  • First published November 2, 2023.
Online issue publication 
November 02, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.